PCI Pharma Services (PCI), a global contract development and manufacturing organization (CDMO), has successfully completed the International Coalition of Medicines Regulatory Authorities (ICMRA) inspection of its Bedford, New Hampshire campus.
McGarrell Reilly has announced that PCI Pharma Services, a pharmaceutical contract development and manufacturing organization (CDMO), has signed a 25-year lease agreement and will construct a new industrial facility at CityNorth Business Campus in Stamullen, Co. Meath, Ireland. With direct access to the M1 motorway, the development offers state-of-the-art facilities, making it an ideal choice for PCI's continued growth in the region.
PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has begun installation of key equipment for its newest sterile fill-finish facility at its Bedford, NH campus. Twin lyophilizers and a state-of-the-art large-scale isolator filling line are currently being installed at the new 50,000-sq.-ft. plant, as part of a multi-year $100 million investment project. Additional equipment will be incorporated in the coming weeks.
New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego
PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report—a detailed overview of its sustainability journey.
Biologics Leadership Expansion with new Center of Excellence Facility Midwest.
Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego
PCI Pharma Services, a biopharma contract manufacturing partner, has unveiled plans for a $50 million expansion at its Rockford, Illinois, sterile injectables site.
Building on PCI’s leadership in this space with its Philadelphia Biotech Center of Excellence, the new facility is the second expansion building off the success in Philadelphia and will house over 20 dedicated customer suites with multiformat machines for the assembly and packaging of vials, pre-filled syringes, auto-injectors, and pen-cartridge combinations. This machinery can be used for the glucagon-like peptide 1 agonists (GLP-1) class of drugs prescribed to treat diabetes and obesity, as well as those needed for oncology treatment and autoimmune diseases.